Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.

Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B.

Ann Rheum Dis. 2014 Jun;73(6):1107-13. doi: 10.1136/annrheumdis-2012-203075. Epub 2013 May 3.

2.

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Baraliakos X, Haibel H, Listing J, Sieper J, Braun J.

Ann Rheum Dis. 2014 Apr;73(4):710-5. doi: 10.1136/annrheumdis-2012-202698. Epub 2013 Mar 16.

PMID:
23505240
3.

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.

Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J.

Rheumatology (Oxford). 2007 Sep;46(9):1450-3. Epub 2007 Jul 10.

PMID:
17623745
4.

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.

van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.

Arthritis Rheum. 2008 Oct;58(10):3063-70. doi: 10.1002/art.23901.

5.

Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.

Braun J, Baraliakos X, Hermann KG, Xu S, Hsu B.

J Rheumatol. 2016 Sep;43(9):1704-12. doi: 10.3899/jrheum.160003. Epub 2016 Jul 15.

PMID:
27422890
6.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.

Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J.

Ann Rheum Dis. 2005 Oct;64(10):1462-6. Epub 2005 Mar 18.

7.

The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients.

Baraliakos X, Listing J, von der Recke A, Braun J.

J Rheumatol. 2009 May;36(5):997-1002. doi: 10.3899/jrheum.080871. Epub 2009 Mar 30.

PMID:
19332632
8.

Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study.

Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, Veeger NJ, van Ooijen PM, Wolf R, Bootsma H, van der Veer E, Arends S.

PLoS One. 2015 Apr 16;10(4):e0122693. doi: 10.1371/journal.pone.0122693. eCollection 2015.

9.

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.

van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R; Canadian (M03-606) study group; ATLAS study group.

Arthritis Res Ther. 2009;11(4):R127. doi: 10.1186/ar2794. Epub 2009 Aug 24.

11.

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.

Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B.

Ann Rheum Dis. 2015 Apr;74(4):757-61. doi: 10.1136/annrheumdis-2014-205862. Epub 2014 Nov 11.

12.

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study.

Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, Baratelle A, Xu S, Xu W, Hsu B.

Ann Rheum Dis. 2012 Jun;71(6):878-84. doi: 10.1136/annrheumdis-2011-200308. Epub 2011 Nov 29. Erratum in: Ann Rheum Dis. 2013 May;72(5):788.

13.

Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors.

Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M, van Ooijen PMA, Wolf R, Veeger NJGM, Bootsma H, Wink FR, Spoorenberg A.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1011-1019. doi: 10.1002/acr.23097. Epub 2017 Jun 9.

PMID:
27696754
14.

Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change.

Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2009 Jun 15;61(6):764-71. doi: 10.1002/art.24425.

15.
16.

TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2. Review.

PMID:
25887212
17.

Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study.

Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, Landewé R.

Ann Rheum Dis. 2015 Jan;74(1):52-9. doi: 10.1136/annrheumdis-2013-204055. Epub 2013 Aug 16. Erratum in: Ann Rheum Dis. 2015 Jul;74(7):1482.

PMID:
23956249
18.

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.

Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D, Xu S, Hsu B.

Arthritis Res Ther. 2016 Dec 28;18(1):304. doi: 10.1186/s13075-016-1200-1.

19.

The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.

Kang KY, Ju JH, Park SH, Kim HY.

Rheumatology (Oxford). 2013 Apr;52(4):718-26. doi: 10.1093/rheumatology/kes364. Epub 2012 Dec 28.

PMID:
23275389
20.

Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).

van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B.

Rheumatology (Oxford). 2013 Feb;52(2):321-5. doi: 10.1093/rheumatology/kes251. Epub 2012 Sep 28.

PMID:
23024015

Supplemental Content

Support Center